Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2010-08-09
2011-12-06
Swartz, Rodney P. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S184100, C424S185100, C424S190100, C424S192100, C435S004000, C435S007100, C435S007200, C435S007320, C530S300000, C530S350000
Reexamination Certificate
active
08071109
ABSTRACT:
The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenicBorreliae, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies.
REFERENCES:
patent: 4801540 (1989-01-01), Hiatt et al.
patent: 5155022 (1992-10-01), Naqui et al.
patent: 5178859 (1993-01-01), Simon et al.
patent: 5187065 (1993-02-01), Schutzer
patent: 5217872 (1993-06-01), Dorward et al.
patent: 5217874 (1993-06-01), Guadagno et al.
patent: 5246844 (1993-09-01), Norris et al.
patent: 5279938 (1994-01-01), Rosa
patent: 5283175 (1994-02-01), Weaver et al.
patent: 5304718 (1994-04-01), Ward et al.
patent: 5324630 (1994-06-01), LeFebvre et al.
patent: 5385826 (1995-01-01), Schell et al.
patent: 5434077 (1995-07-01), Simon et al.
patent: 5436000 (1995-07-01), Barbour et al.
patent: 5571718 (1996-11-01), Dunn et al.
patent: 6475492 (2002-11-01), Philipp et al.
patent: 6610301 (2003-08-01), Motz et al.
patent: 6660274 (2003-12-01), Philipp
patent: 6719983 (2004-04-01), Norris et al.
patent: WO 91/13630 (1991-09-01), None
patent: WO 00/65064 (2000-11-01), None
Appeal by Opponent in European Patent No. EP 0 894 143 (and English translation thereof), including Annexes D4.1-D4.4, D12a-D12d, and D13, filed May 9, 2008.
Balmelii and Piffatetti, “Analysis of the genetic polymorphism ofBorrelia burgdorferisensu lato by multilocus enzyme electrophoresis,”Int. J. Syst. Bacteriol., 46:167-172, 1996.
Barbour and Garon, “Linear plasmids of the bacteriumBorrelia burdorferihave covalently closed ends,”Science, 237:409-411, 1987.
Barbour et al., “Structural analysis of the variable major proteins ofBorrelia hermsii,” J. Exp. Med., 158:2127-2140, 1983.
Barbour et al., “Tandem insertion sequence-like elements define the expression site for variable antigen genes ofBorrelia hermsii,” Infect. Immun., 59:390-397, 1991.
Barbour et al., “Variable antigen genes of the relapsing fever agentBorrelia hermsiiare activated by promoter addition,”Mol. Microbiol., 5:489-493, 1991.
Barbour et al., “Variable major proteins ofBorrelia hermsii,” J. Exp. Med., 156:1312-1324, 1982.
Barbour, “Immunochemical analysis of Lyme disease spirochetes,”Yale J. Biomed., 57:581-586, 1984.
Barbour, “Plasmid analysis ofBorrelia burgdorferi, the Lyme disease agent,”J. Clin. Microbiol., 26(3):475-478, 1988.
Barstad et al., “Variable major proteins ofBorrelia hermsii. Epitope mapping and partial sequence analysis of CNBr peptides,”J. Exp. Med., 161:1302-1314, 1985.
Benach et al., “A murine IgM monoclonal antibody binds an antigenic determinant in outer surface protein A, an immunodominant basic protein of the lyme disease spirochete,”The Journal of Immunology, 140:265-272, 1988.
Berg et al., “The laboratory diagnosis of lyme disease,”Arch. Dermatol., 127:866-870, 1991.
Borenstein et al., “Evidence for surface exposure of a 29kDaBorrelia burgdorferiantigen, ”Abstracts of the Annual Meeting of American Soc. Microbiol., 90(0):46, Abstract B-116, 1990.
Brandt et al. “Immunogenic integral membrane proteins ofBorrelia burgdorferiare lipoproteins,”Infect. Immun., 58(4):983-991, 1990.
Burman et al, “The variable antigens Vmp7 and Vmp21 of the relapsing fever bacteriumBorrelia hermsiiare structurally analogous to the VSG proteins of the African trypanosome,”Molecular Mocrobiology, 4(10);1715-1726, 1990.
Carroll and Gheradini, “Membrane protein variations associated with in vitro passage ofBorrelia burgdorferi,” Infect. Immun., 64:392-398, 1996.
Carter et al.,“ A family of surface-exposed proteins of 20 kilodaltons in the genusBorrelia,” Infect. lmmun., 62:2792-2799, 1994.
Casjens et al., “Linear chromosomes of Lyme disease agent spirochetes: genetic diversity and conservation of gene order,”J. Bacteriol., 177:2769-2780, 1995.
Cluss and Boothby, “Thermoregulation of protein synthesis inBorrelia burgdorferi,” Infect. Immun., 58(4):1038-1042, 1990.
Cunningham et al.,Ann. NY Acad. Sci, 539:376-378, 1988.
Database UniProt Online, “Complement C3 precursor (HSE-MSF) ‘Contains: Complement C3 beta chain; Complement C3 alpha chain; C3a anaphlyatoxin; Complement C3b alpha’ chain; Complement C3c fragment; Complement C3dg fragment; Complement C3g fragment; Complement C3d fragment; Complement C, isoform Short; C3f fragment!. 671 7,” Database Accession No. P01027, 1986.
Dialog Search Report.
Donelson, “Mechanisms of antigenic variation inBorrelia hermsiiand African trypanosomes,”J. Biol. Chem., 270:7783-7786, 1995.
Fawcett et al.,“Detetion of antibodies to the recombinant p39 protein ofBorrelia burgdorferiusing enzyme immunoassay and immunoblotting,”J. Rheumatology, 20(4):734-738, 1993.
GenBank Accession No. AAB09432.
GenBank Accession No. AAB17737.
GenBank Accession No. AAC45733.
Grodzicki and Steere, “Comparison of immunoblotting and indirect enzyme-linked immunosorbent assay using different antigen preparations for diagnosing early lyme disease,”J. Infect. Dis.,157(4):790-797, 1988.
Howe et al.,“ A single recombinant plasmid expressing two major outer surface proteins of the lyme disease spirochete, ”Science, 227:645-646, 1985.
Howe et al., “Organization of genes encoding two outer membrane proteins of the lyme disease agentBorrelia burgdorferiwithin a single transcriptional unit,”Infect. Immun., 54:207-212, 1986.
Hyde et al., “Detection of antigens in urine of mice and humans infected withBorrelia burgdorferi, etiologic agent of lyme disease, ”Journal of Clinical Microbiology, 27(1):58-61, 1989.
Interlocutory Decision in Opposition Proceedings in European Patent No. EP 0 894 143, mailed Jan. 14, 2008.
International Search Report dated Jan. 21, 1995.(PCT/US94/10729).
International Search Report dated Jan. 26, 1993.(PCT/US92/09145).
International Search Report dated Jul. 25, 1997 (PCT/US97/02952).
Jiang et al., “Cross-antigenicity between the major surface proteins (ospA and ospB) and other proteins ofBorrelia burgdorferi,” J. Immun., 144(1):284-289, 1990.
Kalish, “Lyme Disease,”Infect. Arthritis, 19(2):399-426, 1993.
Karlsson, “Western immunoblot and flagellum enzyme-linked immunosorbent assay for serodiagnosis of lyme borreliosis,”J. Clin. Microbiol., 28(9):2148-2150, 1990.
Kitten and Barbour, “Juxtaposition of expressed variable antigen genes with a conserved telomere in the bacteriumBorrelia hermsii,” Proc. Natl. Acad. Sci. USA, 87:6077-6081, 1990.
Kitten et al., “Intragenic recombination and a chimeric outer membrane protein in the relapsing fever agentBorrelia hermsii,” J. Bacteriol.,175(9):2516-2522, 1993.
LeFebvre et al., “Characterization ofBorrelia burgdorferiisolates by restriction endonuclease analysis and DNA hybridization, ”Journal of Clinical Microbiology, 27(4):636-639, 1989.
Letter by Opponent in Preparation of Oral Proceedings to Be Held on Nov. 19, 2007 regarding European Patent No. EP 0 894 143 (and English translation thereof), filed Sep. 19, 2007.
Letter by Patentee in Preparation of Oral Proceedings to Be Held on Nov. 19, 2007 regarding European Patent No. EP 0 894 143 and Declaration of Samuel Kaplan, filed Sep. 19, 2007.
Liang et al., “An immunodominant conserved region within the variable domain of VlsE, the variable surface antigen ofBorrelia burgdorferi,” J. Immunology, 163:5566-5573, 1999.
Liang et al.,
Barbour Alan G.
Hardham John M.
Howell Jerrilyn K.
Norris Steven J.
Weinstock George M.
Board of Regents , The University of Texas System
Fulbright & Jaworski LLP
Swartz Rodney P.
LandOfFree
VMP-like sequences of pathogenic Borrelia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with VMP-like sequences of pathogenic Borrelia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and VMP-like sequences of pathogenic Borrelia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4271493